The Intellectual Property & Science business of Thomson Reuters has released its annual forecast of the drugs to watch in 2014, including three potential blockbuster treatments anticipated to attain more than $1 billion in sales through 2019, after entering the marketplace this year.
The study utilised CortellisTM Competitive Intelligence, the pharmaceutical industry's source for drug pipeline, deals, patents, and company content, to create a Market Insight report identifying drugs that will have significant impact on the marketplace in 2014 and for years to come.
The analysis points to three potential blockbuster drugs include Sovaldi: Gilead's oral NS5B ploymersase inhibitor for treating hepatitis C virus (HCV) was approved by the FDA in December 2013 and is expected to reach a consensus of $2.4 billion in sales in 2014, rising to its peak in sales of an estimated $9.1 billion in 2017.
Anoro Ellipta: GlaxoSmithKline/Theravance's Anoro Ellipta, which contains two bronchodilators for the long-term, once-daily maintenance treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), which is predicted to outsell its developers' 2013 potential blockbuster Relovair in the COPD field, with forecasted sales of $3 billion through 2019.
Idelalisib: Gilead filed this oral P13K p110-delta subunit inhibitor for US approval for indolent non-Hodgkin's lymphoma in September 2013 and for European approval for chronic lymphocytic leukemia (CLL) and INHL in October 2013. A US filing for CLL is also planned. This treatment demonstrated significant efficacy in a phase III CLL trial; however, idelalisib faces stiff competition in the CLL marketplace.
Among those worthy of additional attention are Eli Lilly's long-acting GLP-1 analog dulaglutide for diabetes and its anti-VEGFR2 mAb Cyramza for gastric cancer, as well as MannKind's inhaled insulin product Afrezza. This will be the third filing for Afrezza since 2009, after the FDA twice requested further information.
The Thomson Reuters Market Insight report also includes an update on the 2013 Drugs to Watch, including Vascepa (Amarin), Pomalyst (Celgene), Kadcyla (Roche), and Relovair (GlaxoSmithKline, Thervance).
